C+ — FMP rating1.
Quick AnswerQ3 consensus: revenue $113.6B1, EPS $10.941. Britt Vitalone guided North American Pharmaceutical to 14.5-18.5% (previous 35%) in the Q4 earnings call2. 7 consecutive quarters of beat1.
Content generated by AI editorial engine. Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article.
The median of 6 price targets is $9891, stock is $1061, -6.8% vs the analyst consensus median.
C+ — FMP rating1.
Quick AnswerQ3 consensus: revenue $113.6B1, EPS $10.941. Britt Vitalone guided North American Pharmaceutical to 14.5-18.5% (previous 35%) in the Q4 earnings call2. 7 consecutive quarters of beat1.
Next report
Watchlist
Fy27 Eps Guidance
McKesson guided FY27 adjusted EPS to $43.80-$44.60, implying 12% to 14% year-over-year growth.
"For fiscal 2027, we're establishing an adjusted earnings per diluted share guidance range of $43.80 to $44.60, representing 12% to 14% year-over-year growth."
- Britt Vitalone, CFO - Q4 FY26 Earnings Call - May 7, 2026
Oncology Multispecialty Growth
Oncology and multispecialty revenue rose 35% to $12.7 billion in Q4, driven by provider growth, specialty distribution and acquisitions.
Britt Vitalone, CFO - Q4 FY26 Earnings Call - May 7, 2026Medsurg Apollo Separation
McKesson agreed to sell an approximately 13% minority stake in Medical-Surgical Solutions to Apollo Funds for $1.25 billion, valuing the business at roughly $13 billion of enterprise value.
Brian Tyler, CEO - Q4 FY26 Earnings Call - May 7, 2026Glp1 Distribution
GLP-1 distribution revenue reached $14 billion in Q4, up 22% year over year but down 4% sequentially.
"GLP-1 distribution revenues reached $14 billion in the quarter, an increase of $2 billion or 22% compared to the prior year. However, revenues declined 4% sequentially."
- Britt Vitalone, CFO - Q4 FY26 Earnings Call - May 7, 2026
Ira Branded Price Impact
Branded pharmaceutical price changes under the Inflation Reduction Act weighed on revenue growth, but adjusted segment operating profit still grew double digits in fiscal '26.
Brian Tyler, CEO - Q4 FY26 Earnings Call - May 7, 2026Fy27 Share Repurchases
McKesson plans to repurchase approximately $5 billion of shares in fiscal 2027.
Britt Vitalone, CFO - Q4 FY26 Earnings Call - May 7, 2026Stock Expert AI - Methodology
Historical V1 earnings-model score (archived, Nov 8, 2026) — not the current MoonshotScore. Current MoonshotScore: MCK stock page
multi-pillar methodology. Cash Runway and News Sentiment strong. Revenue Growth weak.
How is it calculated? ->6 investor frameworks. 1 bullish (Ken Griffin), 3 bearish (Jim Simons, Klarman, Munger), 2 neutral (Ray Dalio, Buffett).
How is it calculated? ->Quality business, but price is high.
How is it calculated? ->Past Performance
Q2 FY27 (November 4, 2026) EPS $11.68 vs $10.72 estimate: beat (+9.0%)1.
"In the oncology and multispecialty segment, we anticipate revenue growth of 14.5% to 18.5% and operating profit growth of 13.5% to 17.5%."
- Britt Vitalone, CFO - Q4 FY26 Earnings Call - May 7, 2026
No RPO/backlog concentration disclosed in Q4 earnings call.
Form 4 Q2 FY27: 6 transactions, net -$9.23M1.
6 transactions · 6 sales / 0 purchases = net negative flow. Not large in absolute terms against a $123.7B market cap.
Not advice - a structural framework for earnings night. Decision discipline is yours.
Market Outlook
You read it in 5 minutes. When the numbers come out on Wednesday evening - you know what you're looking at.
Data arrives at night. The framework is ready now.
Data arrives on Wednesday evening. The framework is ready on this page: Q3 EPS threshold $10.941, North American Pharmaceutical guidance 14.5-18.5%2, CapEx threshold "below $123.0M". Three anchors, three scenarios.
Comparison Stock Expert AI is free today — no credit card.
Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts
Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing
Stock Expert AI is free today — no credit card. Council 6-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.
Educational tool, not investment advice. Past performance does not guarantee future results.
Calendar
DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.
This McKesson Corporation (MCK) Q3 FY27 earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.
McKesson Corporation (MCK): Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.
McKesson Corporation (MCK): Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.
McKesson Corporation (MCK): No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.